Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Payables (2016 - 2025)

Historic Payables for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $2.3 million.

  • Immucell's Payables fell 722.39% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 722.39%. This contributed to the annual value of $2.5 million for FY2024, which is 1686.1% up from last year.
  • According to the latest figures from Q3 2025, Immucell's Payables is $2.3 million, which was down 722.39% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Payables ranged from a high of $2.6 million in Q2 2025 and a low of $1.2 million during Q2 2021
  • Its 5-year average for Payables is $1.9 million, with a median of $2.0 million in 2025.
  • Per our database at Business Quant, Immucell's Payables surged by 4330.3% in 2022 and then tumbled by 813.37% in 2025.
  • Quarter analysis of 5 years shows Immucell's Payables stood at $1.6 million in 2021, then grew by 23.95% to $2.0 million in 2022, then grew by 6.17% to $2.1 million in 2023, then increased by 16.86% to $2.5 million in 2024, then fell by 6.4% to $2.3 million in 2025.
  • Its Payables was $2.3 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.0 million in Q1 2025.